How do you price tiers for a remote patient monitoring platform in 2027?

What pricing model should an RPM platform use in 2027 — PMPM, per-device, or flat SaaS?

The winning default is PMPM anchored on enrolled or actively-monitored patients, with clearly separated cost components so buyers can model their own margin. A flat SaaS seat fee misaligns with how RPM value accrues: value scales with patient census and billable encounters, not with the number of admin logins. A pure per-device fee, meanwhile, punishes customers for the exact behavior you want — enrolling and retaining patients — and it ties your revenue to hardware churn rather than clinical engagement. Anchoring on the active patient keeps your pricing legible to a CFO who is comparing your fee against reimbursement per patient per month.

That said, "PMPM" alone hides real cost drivers, so tier design in 2027 should decompose the price into three transparent layers: a platform/software fee (the recurring per-patient license), a device layer (buy, lease, or bring-your-own, plus logistics, replacement, and connectivity), and a service layer (whether you provide monitoring staff, escalation, and clinical triage or the customer does it themselves). Making these visible lets a small clinic buy software-only and self-monitor, while a health system buys a fully-managed program — the same platform, different tier, very different price. This decomposition is also what lets you defend margin when a buyer says "your competitor is cheaper": you can show which layer they're actually comparing. For the broader logic of aligning price to realized value, see value-based pricing patterns.

How should you tier a remote patient monitoring platform by clinical and reimbursement value?

Tier boundaries should map to the *programs a customer can run and bill*, because that is the unit of value they experience. A practical three-plus-one ladder works across most markets: an entry tier that covers a single condition and self-service monitoring, a growth tier that adds multiple conditions and additional reimbursable program types (for example, layering chronic care management or principal care management alongside core RPM), a scale tier that adds managed clinical services and multi-site rollout, and a custom enterprise tier for large systems. Each step up should unlock more *billable surface area* and more *labor offloaded from the customer*, which is what justifies a higher per-patient rate.

Crucially, do not tier on trivial feature gates that clinicians will resent — things like read-only dashboards, basic alerting, or data export should live in every tier because withholding them creates safety and trust problems in a clinical context. Reserve the upgrade triggers for capabilities that genuinely change economics: additional condition modules, deeper EHR integration, managed monitoring staff, advanced analytics and population-health cohorting, white-labeling, and compliance/SLA guarantees. The diagram below shows how a buyer typically moves up the ladder as their program matures.

The upgrade path matters as much as the tiers themselves: your growth motion is expansion within an account — more patients, more conditions, more sites — so design tiers that reward that expansion instead of forcing a disruptive re-platforming at each step. A good rule is that moving from one tier to the next should feel like turning on a module, not signing a new contract.

How do you account for hardware, connectivity, and logistics in RPM tiers?

Devices are where naïve RPM pricing quietly goes underwater. A blood-pressure cuff, glucometer, pulse oximeter, or connected scale is not a one-time cost — it carries shipping, patient onboarding, cellular or Bluetooth connectivity, warranty and replacement, returns, sanitization, and end-of-life. If you bundle "free devices" into a flat per-patient fee, you inherit all of that variance while your revenue stays fixed, and a single high-churn account can erase the margin from ten stable ones. The safer structure separates the device layer explicitly and offers three postures: customer-owned (they buy hardware outright, you charge software-only), leased/managed (you own logistics and charge a device fee per active patient), and bring-your-own-device where clinically appropriate.

Connectivity deserves its own line because cellular-enabled devices carry recurring carrier cost that Bluetooth-to-phone models do not, and the choice affects both your COGS and the patient population you can serve (elderly patients with no smartphone often need cellular). Build these as add-ons or tier inclusions rather than hidden assumptions. The map below shows how the cost components stack into a defensible per-patient price.

Because reimbursement rules and covered device categories shift over time, keep the device layer contractually flexible — annual true-ups, replacement caps, and a clear policy on lost or damaged units. Tie your device-refresh assumptions to realistic patient retention data rather than best-case adherence, and revisit them as your cohort matures. For how to model recurring-cost variance against a fixed fee, our note on margin protection in usage-heavy SaaS walks through the guardrails.

How does reimbursement and regulation shape RPM pricing in 2027?

RPM pricing cannot be set in a vacuum from the billing landscape, because your customers' willingness to pay is bounded by what they can collect. Reimbursement for remote monitoring in the U.S. runs through defined program codes (RPM, and adjacent programs like remote therapeutic monitoring, chronic care management, and principal care management), each with its own requirements around data-collection days, interactive time, and eligible practitioners. Your tiers should make it easy for a customer to satisfy those requirements — enrollment tracking, time capture, and audit-ready documentation are not premium features in 2027, they are table stakes, because a program that can't survive an audit has negative value.

Keep the specifics general in your public pricing because these rules change: code definitions, thresholds, and covered scenarios are periodically revised by regulators and payers, and any hard number you print risks going stale or, worse, misleading a buyer into a compliance gap. Instead, price the *capability to run compliant programs* and let your implementation and customer-success teams handle the current specifics. Internationally, reimbursement varies dramatically, so a globally-sold platform needs region-aware tiers rather than one U.S.-centric price sheet. The overarching principle: sell against the customer's reimbursement math, but never encode a specific reimbursement figure into your list price, and revisit tier economics whenever the regulatory floor moves.

When should you offer outcomes-based or risk-shared pricing for RPM?

Outcomes-based pricing — where part of your fee is tied to reduced readmissions, improved adherence, or lower total cost of care — is attractive to sophisticated buyers like health systems and at-risk provider groups, but it is an *advanced* tier, not a default. Offer it only when three conditions hold: the buyer bears financial risk for the outcome (so they actually value moving it), you have a clean measurement methodology both sides trust, and you have enough deployment history to price the risk without gambling your margin. For everyone else, a straightforward PMPM with clear program economics converts faster and is far easier to forecast.

When you do offer it, structure it as a hybrid: a reduced base PMPM plus an outcomes bonus, rather than a pure at-risk fee, so you are never fully exposed to factors outside your control (patient behavior, comorbidities, clinical staffing you don't manage). Cap both the upside and downside, define the baseline and attribution rules in writing before go-live, and treat the outcomes tier as a land-and-expand tool for your most strategic accounts. Done well, it deepens the relationship and creates switching costs; done carelessly, it turns your revenue into a bet on someone else's clinical operations.

What common pricing mistakes should RPM platforms avoid?

The recurring failures are predictable. First, bundling unlimited devices into a flat fee — it feels generous and closes deals, but it transfers all hardware and logistics variance onto you. Second, tiering on safety-critical features like alerting or data export, which erodes clinical trust and invites churn. Third, printing specific reimbursement figures in list pricing, which ages badly and creates liability. Fourth, ignoring the services line — if you provide monitoring staff, that clinical labor is your largest variable cost and must be priced explicitly, not hidden inside "platform fee." Fifth, no expansion path, forcing a re-contract at every growth step and stalling your own net revenue retention.

The meta-mistake is treating RPM like generic horizontal SaaS. It is a regulated, hardware-and-labor-intensive clinical business, and its pricing has to reflect all four dimensions simultaneously. The platforms that win in 2027 make the customer's ROI arithmetic obvious, keep the entry tier low-friction, decompose cost drivers transparently, and design every tier boundary around a real change in value delivered — more conditions, more billable programs, more labor offloaded, stronger guarantees. For a structured way to pressure-test any tier ladder against buyer willingness-to-pay, see our tier-design teardown.

Related questions

Should RPM devices be included in the subscription price?

Usually no — separate the device layer so you don't absorb hardware, logistics, and replacement variance against a fixed fee. Offer buy, managed-lease, and BYOD options, and price connectivity (cellular vs. Bluetooth) explicitly.

What is the difference between PMPM and per-device pricing?

PMPM charges per enrolled/active patient per month, aligning revenue with clinical engagement and reimbursement. Per-device charges per unit deployed, which penalizes enrollment and ties your revenue to hardware churn instead of retention.

How many pricing tiers should an RPM platform have?

Three to four: an entry/self-service tier, a growth tier that adds conditions and managed alerts, a scale tier with managed clinical services, and a custom enterprise tier. Fewer feels thin to enterprise; more confuses buyers.

Is outcomes-based pricing worth it for RPM vendors?

Only for at-risk buyers with trustworthy measurement and enough deployment history to price the risk. Structure it as base PMPM plus a capped bonus — never fully at-risk — and use it to deepen strategic accounts.

How do you price RPM for international markets?

Build region-aware tiers, because reimbursement, covered devices, and regulation vary sharply by country. Never reuse a U.S.-centric price sheet globally; localize both the economics and the compliance capabilities each region requires.

FAQ

What should be included in the base RPM tier? The entry tier should cover a single condition or program, core monitoring dashboards, alerting, data export, and audit-ready documentation — all the safety-critical and compliance basics. Device posture is typically BYOD or customer-owned at this level, and the customer self-monitors. The goal is a low-friction "land" that lets a small clinic run one compliant program and prove value before expanding.

How do you decide what goes in higher tiers versus the base? Gate on capabilities that change economics or offload labor: additional condition modules, more billable program types, managed monitoring staff, deep EHR integration, population-health analytics, white-labeling, and SLA guarantees. Never gate safety features. If a locked feature would create a clinical risk or a compliance gap, it belongs in every tier.

How should managed monitoring services be priced? As an explicit service layer, because clinical staff are your largest variable cost. Price it per active patient or per program, separate from the software license, so buyers who self-monitor aren't subsidizing those who don't. This also lets you scale the service tier's margin independently of the platform tier.

How do you handle device costs without losing margin? Separate the device layer and offer buy, lease/managed, and BYOD options. When you own logistics, charge a per-active-patient device fee that accounts for shipping, connectivity, warranty, replacement, and returns — and cap replacements. Base your device-refresh assumptions on realistic retention data, not best-case adherence.

Can you print reimbursement numbers in your pricing? Avoid it. Reimbursement codes, thresholds, and covered scenarios are periodically revised by regulators and payers, so any figure you publish risks going stale or misleading a buyer into a compliance gap. Price the capability to run compliant, billable programs and let customer success handle current specifics.

How should RPM pricing change as an account grows? Design for in-account expansion: more patients, more conditions, more sites should raise revenue smoothly without a disruptive re-platforming. Volume-based PMPM breakpoints and modular condition add-ons let net revenue retention climb naturally. Forcing a new contract at every growth step stalls your own expansion motion.

Should startups and enterprises get the same tier structure? The same ladder, different entry points. A startup or single clinic lands on entry or growth and self-serves; an enterprise health system lands on scale or custom with managed services, integrations, and SLAs. Keep the platform identical so upgrades are module toggles, not migrations.

How do you defend price against a cheaper competitor? Decompose the price into platform, device, connectivity, and service layers so you can show exactly which layer the buyer is comparing. Often the "cheaper" competitor has excluded logistics or clinical labor. Transparent cost components turn a price fight into a value-and-scope conversation.

Sources

• Centers for Medicare & Medicaid Services (CMS)
• CMS Physician Fee Schedule
• American Medical Association — CPT
• HealthIT.gov — Telehealth and Remote Monitoring
• American Telemedicine Association
• U.S. Food & Drug Administration — Digital Health
• HHS — HIPAA for Professionals
• Office of the National Coordinator for Health IT
• OpenView — SaaS Pricing Resources
• KLAS Research — Healthcare IT

Related on PULSE

• Value-based pricing patterns
• Margin protection in usage-heavy SaaS
• Tier-design teardown
• How to price a SaaS platform with hardware costs
• Land-and-expand pricing motions